Biohaven Ltd. (NYSE:BHVN) Stock Has Consensus Target Price of $19.25 According to Brokerages

Shares of Biohaven Ltd. (NYSE:BHVN) have been assigned a consensus rating of “Moderate Buy” from the seventeen ratings firms that are currently covering the company, Marketbeat.com reports. Two research analysts have rated the stock with a sell recommendation, five have assigned a hold recommendation, eight have given a buy recommendation and two have issued a strong buy recommendation on the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $20.06.

Several equities research analysts recently issued reports on BHVN shares. Canaccord Genuity Group increased their price objective on Biohaven from $21.00 to $32.00 and gave the stock a “buy” rating in a research note on Friday, October 30th. Robert W. Baird set a $48.00 target price on Biohaven in a research note on Thursday, October 22nd. TD Cowen reiterated a “buy” rating on shares of Biohaven in a report on Wednesday, August 26th. Wall Street Zen upgraded Biohaven from a “sell” rating to a “hold” rating in a report on Saturday, October 24th. Finally, Raymond James Financial reissued a “strong-buy” rating on shares of Biohaven in a research report on Thursday, October 8th.

Institutional Trading of Biohaven

Several hedge funds and other institutional investors have recently modified their holdings of BHVN. Commonwealth Equity Services LLC acquired a new position in Biohaven in the 3rd quarter worth about $135,000. Profund Advisors LLC raised its stake in shares of Biohaven by 5.6% during the 3rd quarter. Profund Advisors LLC now owns 57,036 shares of the company’s stock worth $761,000 after purchasing an additional 3,018 shares in the last quarter. Sigma Planning Corp raised its stake in shares of Biohaven by 43.1% during the 3rd quarter. Sigma Planning Corp now owns 19,944 shares of the company’s stock worth $266,000 after purchasing an additional 6,008 shares in the last quarter. Sterling Capital Management LLC lifted its stake in Biohaven by 847.5% in the third quarter. Sterling Capital Management LLC now owns 4,444 shares of the company’s stock valued at $59,000 after acquiring an additional 3,975 shares during the last quarter. Finally, Inspire Investing LLC increased its stake in shares of Biohaven by 2.4% during the 3rd quarter. Inspire Investing LLC now owns 47,089 shares of the company’s stock worth $629,000 after purchasing an additional 1,113 shares during the last quarter. 88.78% of the stock is currently owned by hedge funds and other institutional investors.

Biohaven Trading Down 2.5%

NYSE BHVN opened at $15.22 on Monday. Biohaven has a twelve month low of $7.48 and a twelve month high of $18.24. The company has a debt-to-equity ratio of 21.23, a quick ratio of 3.05 and a current ratio of 3.05. The stock has a market cap of $2.30 billion, a price-to-earnings ratio of -3.94 and a beta of 1.36. The firm’s 50 day moving average price is $13.71 and its two-hundred day moving average price is $12.30.

Biohaven (NYSE:BHVN) last released its earnings results on Monday, August 10th. The company reported ($0.91) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.15). Equities analysts anticipate that Biohaven will post -3.11 EPS for the current year.

About Biohaven

Biohaven Ltd. (NYSE:BHVN) is a biopharmaceutical company focused on discovering, developing and commercializing therapies for neurological and neuropsychiatric diseases, as well as certain immunological and rare disorders. The company’s research activities include small-molecule medicines, monoclonal antibodies and other innovative therapeutic approaches.

Biohaven’s pipeline has included investigational treatments for conditions such as migraine, obsessive-compulsive disorder, spinal muscular atrophy, amyotrophic lateral sclerosis, mood disorders and autoimmune diseases.